Robert Nelsen

Robert Nelsen

Fondatore presso SANA BIOTECHNOLOGY, INC.

Patrimonio netto: 4 M $ in data 31/05/2025

61 anni
Health Technology
Commercial Services
Finance

Profilo

Robert Nelsen is a co-founder and a Managing Director of ARCH Venture Partners.
Some of his notable early-stage investments include Illumina (ILMN), Alnylam Pharmaceuticals (ALNY), June Therapeutics (JUNO – acquired by Celgene), Beam Therapeutics (BEAM), Karuna Therapeutics (KRTX), Altos Labs, EQRx (EQRX), National Resilience, Prime Medicine, Lyell Immunopharma (LYEL), Array BioPharma (ARRY – acquired by Pfizer), Hua Medicine (2552:HK), Vir Biotechnology (VIR), Insitro, Agios Pharmaceuticals (AGIO), Sage Therapeutics (SAGE), GRAIL (acquired by Illumina), Gossamer Bio (GOSS), Ikaria (acquired by Mallinckrodt), Kythera Biopharmaceuticals (KYTH – acquired by Allergan), Receptos (RCPT – acquired by Celgene), Aviron (AVIR – acquired by MedImmune), Denali Therapeutics (DNLI), Syros Pharmaceuticals (SYRS), Sana Biotechnology (SANA), Verve Therapeutics (VERV), Brii Biosciences (2137:HK), Bluebird Bio (BLUE), R2 Technology (acquired by Hologic), Caliper Life Sciences (CALP – acquired by PerkinElmer), Trubion Pharmaceuticals (TRBN – acquired by Emergent Biosolutions), Adolor (ADLR – acquired by Cubist Pharmaceuticals), deCODE Genetics (DCGN – acquired by Amgen), Editas (EDIT), 10x Genomics, Semma Therapeutics (acquired by Vertex Pharmaceuticals), Element, and IDUN Pharmaceuticals (acquired by Pfizer).
Mr. Nelsen is a director of VIR, SANA, LYEL, National Resilience, Insitro, Prime Medicine, Nutcracker Therapeutics, Neumora Therapeutics, Brii Biosciences, and serves as Chairman of Hua Medicine, among others.
He previously served as a Trustee of the Fred Hutchinson Cancer Research Institute, the Institute of Systems Biology, and was a director of the National Venture Capital association.
Mr. Nelsen holds an M.B.A. from the University of Chicago and a B.S.
from the University of Puget Sound with majors in Economics and Biology.

Partecipazioni note in società pubbliche

SocietàDataNumero di azioniValorizzazioneData di valutazione
30/05/2024 618.041 ( 0,45% ) 3 M $ 31/05/2025
31/03/2025 60.615 ( 0,06% ) 959 535 $ 31/05/2025
31/12/2023 150.000 ( 0,01% ) 52 223 $ 31/05/2025
05/06/2025 13.853 ( 0,01% ) 30 061 $ 31/05/2025
04/06/2025 16.080 ( 0,01% ) 18 974 $ 31/05/2025

Posizioni attive di Robert Nelsen

SocietàPosizioneInizio
HUA MEDICINE (SHANGHAI) LTD. Presidente 23/04/2010
SANA BIOTECHNOLOGY, INC. Fondatore 13/07/2018
PRIME MEDICINE, INC. Direttore/Membro del Consiglio 01/09/2020
Fondatore 28/06/2010
Hua Medicine Technology (Hong Kong) Ltd.
Direttore/Membro del Consiglio 01/08/2010
Direttore/Membro del Consiglio -
Direttore/Membro del Consiglio -
Fondatore 01/01/1986
Direttore/Membro del Consiglio -
░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ -
░░░░░ ░░░░░░░ ░░░░ ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ -
░░░░░░░░ ░░░░░░░░░░░ ░░░░ ░░░░░░░░░░ -
Tutte le posizioni attive di Robert Nelsen

Precedenti posizioni note di Robert Nelsen

SocietàPosizioneFine
░░░ ░░░░░░░░░░░░░░ ░░░░ ░░░░░░░░░ ░░░░░░░░░░
░░░░░ ░░░░░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ ░░░░░░░░░░
░░░░ ░░░░░░░░░░░ ░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ ░░░░░░░░░░
░░░░░░ ░░░░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ ░░░░░░░░░░
░░░░░░░░░░ ░░░░░░░░░░ ░░░░░░░░░░░ ░░░░░ ░░░░░░░░░ ░░░░░░░░░░
Vedi nel dettaglio l'esperienza di Robert Nelsen

Formazione di Robert Nelsen

University of Puget Sound
Undergraduate Degree
The University of Chicago Booth School of Business
Masters Business Admin

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Robert Nelsen

Relazioni

99

Relazioni di 1° grado

80

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa21
ILLUMINA, INC.

Health Technology

GRAIL, INC.

Health Technology

BRII BIOSCIENCES LIMITED

Commercial Services

LYELL IMMUNOPHARMA, INC.

Health Technology

PRIME MEDICINE, INC.

Health Technology

Mondo

Health Technology

SANA BIOTECHNOLOGY, INC.

Health Technology

GOSSAMER BIO, INC.

Health Technology

BEAM THERAPEUTICS INC.

Health Technology

VIR BIOTECHNOLOGY, INC.

Health Technology

UNITY BIOTECHNOLOGY, INC.

Health Technology

CYCLACEL PHARMACEUTICALS, INC.

Health Technology

DENALI THERAPEUTICS INC.

Health Technology

BELLEROPHON THERAPEUTICS, INC.

Health Technology

SAGE THERAPEUTICS, INC.

Health Technology

SYROS PHARMACEUTICALS, INC.

Health Technology

AGIOS PHARMACEUTICALS, INC.

Health Technology

HUA MEDICINE (SHANGHAI) LTD.

Health Technology

SIENNA BIOPHARMACEUTICALS, INC.

Health Technology

FATE THERAPEUTICS, INC.

Health Technology

NEUMORA THERAPEUTICS, INC.

Health Technology

Aziende private57

Finance

Consumer Services

Process Industries

Health Technology

Miscellaneous

Health Technology

Commercial Services

Commercial Services

Health Technology

Finance

Health Technology

Energy Minerals

Health Technology

Health Technology

Technology Services

Health Technology

Health Technology

Finance

Health Technology

Commercial Services

Producer Manufacturing

Commercial Services

Health Technology

Finance

Health Technology

Health Technology

Health Services

Health Technology

Health Technology

Health Services

Saga Investments LLC

Finance

Health Technology

Health Technology

Commercial Services

Finance

Commercial Services

Finance

Technology Services

Hua Medicine Technology (Hong Kong) Ltd.

Health Technology

Commercial Services

Electronic Technology

Brii Biosciences (Beijing) Co. Ltd.

Commercial Services

Commercial Services

Finance

Health Technology

Brii Biosciences (Hong Kong) Co. Ltd.

Health Technology

Health Technology

Health Services

Finance

Health Technology

Health Technology

Health Services

Technology Services

Resilience, Inc.

Commercial Services

Vedi le connessioni aziendali